Wolfgang A Seghezzi

7422885, Sep 9, 2008

Sep 17, 2004

10/943438

Thierry O. Fischmann - Scotch Plains NJ, US
Vincent S. Madison - Mountain Lakes NJ, US
Alan William Hruza - Hackettstown NJ, US
Paul Reichert - Montville NJ, US
Lata Ramanathan - West Orange NJ, US
David Paul Sanden - San Francisco CA, US
Wolfgang Seghezzi - Mountain View CA, US

Schering Corporation - Kenilworth NJ

C12N 9/12
G01N 31/00

435194, 436 4

The present invention discloses nucleic acids that encode an active human Aurora 2 kinase catalytic domain. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active human Aurora 2 kinase catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of human Aurora 2 kinase. In addition, the present invention discloses methods of using the X-ray diffractable crystals of human Aurora 2 kinase in structure assisted drug design to identify compounds that can modulate the enzymatic activity of human Aurora 2 kinase.

7608643, Oct 27, 2009

Mar 7, 2006

11/370005

Ronald J. Doll - Convent Station NJ, US
Ronald Herbst - Palo Alto CA, US
Wolfgang Seghezzi - Mountain View CA, US
Emma M. Lees - Oakland CA, US
William F. Estacio - San Lorenzo CA, US

Schering Corporation - Kenilworth NJ

A01N 35/04
A61K 31/541
A01N 43/90
A61K 31/519
A61K 31/12
C07D 419/04
C07D 417/00

514683, 544279, 544284, 514292, 5142601, 5142641, 5142651, 514290, 546 83

The present invention relates to compounds of Formula I or pharmaceutically acceptable salts or solvates thereof:.

7824491, Nov 2, 2010

Aug 1, 2008

12/184770

Thierry O. Fischmann - Scotch Plains NJ, US
Vincent S. Madison - Ukiah CA, US
Alan William Hruza - Hackettstown NJ, US
Paul Reichert - Montville NJ, US
Lata Ramanathan - Cambridge NJ, US
David Paul Sanden - San Francisco CA, US
Wolfgang Seghezzi - Mountain View CA, US

Schering Corp. - Kenilworth NJ

C30B 28/06
G01N 31/00
C12N 9/12

117 70, 436 4, 435194

The present invention discloses nucleic acids that encode an active human Aurora 2 kinase catalytic domain. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active human Aurora 2 kinase catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of human Aurora 2 kinase. In addition, the present invention discloses methods of using the X-ray diffractable crystals of human Aurora 2 kinase in structure assisted drug design to identify compounds that can modulate the enzymatic activity of human Aurora 2 kinase.

62743120, Aug 14, 2001

Dec 10, 1997

8/999774

Kurt C. Gish - Sunnyvale CA
Wolfgang Seghezzi - Mountain View CA
Frances Shanahan - Mountain View CA
Emma M. Lees - San Francisco CA
Terrill K. McClanahan - Sunnyvale CA

Schering Corporation - Kenilworth NJ

C12Q 168
C07H 2104
C12P 2106
C12N 1500

435 6

Purified genes encoding intracellular regulatory molecules from a human, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.

20220340660, Oct 27, 2022

Oct 1, 2019

17/762530

- Rahway NJ, US
Jin-Hwan Han - Mountain View CA, US
Drake Maurice LaFace - Half Moon Bay CA, US
Elaine Pinheiro - Needham MA, US
Wolfgang Seghezzi - Mountain View CA, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07K 16/28
A61P 35/00
C07K 14/705
A61K 31/506

Novel methods for selecting a patient with a cancer for treatment with a TIGIT antagonist are disclosed. The methods employ various biomarkers, including CD45, CD3ε, CD11b, Foxp3, IFN-γ, Cxcl11, Cxcl10, TNF-α, IL-23, MHC class II, CD80, CD86, and CD40.

20210017276, Jan 21, 2021

Jul 27, 2020

16/939883

- Rahway NJ, US
Wolfgang Seghezzi - Mountain View CA, US
Linda Liang - Mountain View CA, US
Veronica Juan - Redwood City CA, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07K 16/28
A61P 31/00
A61K 39/395

The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.

20200392197, Dec 17, 2020

Aug 27, 2020

17/004395

- Rahway NJ, US
- La Jolla CA, US
Robert M. Garbaccio - Lansdale PA, US
Wolfgang Seghezzi - Mountain View CA, US
Elisabetta Bianchi - Pomezia, IT
Federica Orvieto - Pomezia, IT
Dennis Gately - San Diego CA, US
Nick Knudsen - Escondido CA, US
Anthony Manibusan - San Diego CA, US

Merck Sharp & Dohme Corp. - Rahway NJ
Ambrx, Inc. - La Jolla CA

C07K 14/605
C07K 16/26
C07K 16/28
A61K 47/68
A61P 3/10

Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

20200270346, Aug 27, 2020

May 15, 2020

16/806658

- Rahway NJ, US
Drake LaFace - Half Moon Bay CA, US
Gopalan Raghunathan - San Diego CA, US
Linda Liang - Mountain View CA, US
Wolfgang Seghezzi - Mountain View CA, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07K 16/28
A61K 39/395
A61K 45/06

The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.